Seeking Alpha

The FDA has approved a companion diagnostic test for Roche's (RHHBY.OB +0.5%) cancer drug...

The FDA has approved a companion diagnostic test for Roche's (RHHBY.OB +0.5%) cancer drug Tarceva, which detects certain gene mutations present in some non-small cell lung cancers. The cobas epidermal growth factor receptor, or EGFR, Mutation Test is the first FDA-approved companion diagnostic that detects a kind of gene mutation present in about 10% of non-small cell lung cancers, and, together with the drug, will be used as a first line treatment.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs